Your session is about to expire
← Back to Search
Immune Checkpoint Inhibitors + Axitinib for Kidney Cancer
Study Summary
This trial will study a new drug combo to treat unresectable kidney cancer, to see if it's safer and more effective than existing treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I cannot swallow pills or have a condition that affects how my body absorbs nutrients.I have a history of congenital QT syndrome.I need IV fluids, nutrition, or tube feeding due to GI issues.I have not had severe bleeding in the last 28 days.You have a condition that causes abnormal bleeding or blood clotting.I haven't had major blood vessel problems or surgery for them in the last 6 months.I have had cancer spread to the lining of my brain and spinal cord.I have not had a severe infection in the last 4 weeks.I have not had a major heart or stroke event in the last 3 months.I do not have any current stomach or digestive system issues.I haven't had cancer other than kidney cancer in the last 2 years, except for very low-risk types.I haven't taken any immune-weakening drugs in the last 2 weeks and don't expect to need any during the study.I have had a severe hypertension crisis or brain issues due to high blood pressure.Your heart beats too fast when you are resting.I frequently need procedures to remove excess fluid from my body.I am using or might need strong medication that affects liver enzymes.You have or had a condition where your immune system attacks your own body or you have a weak immune system.You have air in your abdomen that isn't from a recent surgery or a specific medical procedure.My high blood pressure is not under control.My cancer has spread to the blood vessels in my lungs or caused lung cavities.I haven't had significant bleeding or blood disorders in the last 3 months.I am allergic to certain medications or their ingredients.My kidney cancer is classified as intermediate or poor risk.My cancer has spread to my digestive system.I have at least one tumor that can be measured.I have received treatments for kidney cancer, including immune therapies.I have brain metastases that are untreated or getting worse.I am not pregnant or breastfeeding and do not plan to become pregnant during the study or within the specified time after the last dose.I have a history of specific lung conditions or signs of lung inflammation on a CT scan.I have not had a stroke, heart attack, or blood clot in the last 3 months.I have active tuberculosis.I have not had an abdominal abscess in the last 6 months.I haven't had major surgery in the last 4 weeks and don't expect to need one during the study.I have not taken any strong antibiotics in the last 2 weeks.I am fully active or restricted in physically strenuous activity but can do light work.My liver function is significantly impaired.I have not received a live vaccine in the last 4 weeks and do not plan to during the study.You do not have HIV, hepatitis B, or hepatitis C.I have had a previous transplant of stem cells or an organ.My cancer causes me pain that my current medication doesn't control.I have a history of serious irregular heartbeats.You have an ongoing Epstein-Barr virus (EBV) infection or suspected long-term EBV infection.I have high calcium levels in my blood that are not under control or cause symptoms.My kidney cancer is confirmed by a lab test.
- Group 1: Arm A (Tobemstomig + Axitinib)
- Group 2: Arm B (Tobemstomig + Tiragolumab + Axitinib)
- Group 3: Control Arm (Pembrolizumab + Axitinib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still opportunities to become a participant in this research project?
"According to the clinical trial registry, recruitment is ongoing for this medical study. The initial posting was on April 21st 2023 and there have been subsequent updates as recently as April 26th of that same year."
What potential risks or side effects accompany the administration of Arm B (RO7247669 + Tiragolumab + Axitinib) to patients?
"Arm B (RO7247669 + Tiragolumab + Axitinib) was assigned a rating of 2 due to the fact that this is only at Phase 2, meaning it has been demonstrated safe but its effectiveness still requires further investigation."
Are there multiple sites in this state offering participation in the trial?
"There are 9 sites that have begun recruiting for this medical study, including Thompson Cancer Survival Center in Knoxville, Sunshine Coast University Hospital; The Adem Crosby Centre in Birtinya, and ICON Cancer Care Adelaide in Kurralta Park. Additionally, other centres across the nation are part of the trial too."
Is there a set quota of participants for the clinical trial?
"Indeed, the trial is actively recruiting. Initially published on April 21st 2023 and most recently amended on April 26th of the same year, this medical study requires 210 participants to be recruited across 9 different clinical sites."
Share this study with friends
Copy Link
Messenger